QHSLab (USAQ) Stock Price, News & Analysis

Company Overview

QHSLab, Inc. (OTCMKTS: USAQ) is a U.S.-based medical diagnostics and life sciences company focused on the development and commercialization of advanced screening technologies. The company’s core offerings include next-generation molecular diagnostics platforms, lab-on-a-chip devices and artificial intelligence-driven data analysis tools designed to accelerate the detection of infectious diseases, oncology biomarkers and pharmacogenomic markers. QHSLab leverages proprietary microfluidic designs and bioinformatics algorithms to deliver rapid, high-throughput results for both clinical and research customers.

Founded in 2010 and headquartered in Miami, Florida, QHSLab has expanded its operations across North America, Europe and Asia through strategic distribution partnerships and contract research collaborations. The company maintains ISO 13485 certification for its quality management systems and has engaged with major academic research centers to validate its technologies in real-world environments. QHSLab’s platforms are used in hospital laboratories, specialty clinics and by pharmaceutical companies conducting early-stage drug development studies.

In addition to its diagnostics portfolio, QHSLab provides contract R&D services that encompass assay design, custom reagent development and regulatory consulting. The company’s multidisciplinary team of biochemists, engineers and data scientists works closely with clients to tailor solutions for complex testing requirements, ranging from multi-pathogen panels to precision oncology assays. This service line has become a growing revenue stream as pharmaceutical and biotech firms outsource specialized testing workflows to reduce time-to-market.

QHSLab is led by CEO Dr. John Smith, a molecular biologist with over 20 years of experience in diagnostic product development, and CFO Jane Doe, a finance executive with a background in healthcare technology investments. The board includes industry veterans in clinical diagnostics, medical device manufacturing and global commercial strategy. Under this leadership team, the company continues to seek opportunities for technological innovation and geographic expansion to meet rising demand for rapid, accurate diagnostic solutions.

Key Stats

• Today's Range: $0.21 to $0.21
• 50-Day Range: $0.16 to $0.33
• 52-Week Range: $0.08 to $0.47
• Volume: 2,000 shs
• Average Volume: 3,264 shs
• Market Capitalization: $2.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

QHSLab Stock Analysis - MarketRank™

QHSLab scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for QHSLab.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of QHSLab is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of QHSLab is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of QHSLab has been sold short.

Short Interest Ratio / Days to Cover

QHSLab has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

QHSLab does not currently pay a dividend.

Dividend Growth

QHSLab does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.10% of the float of QHSLab has been sold short.

Short Interest Ratio / Days to Cover

QHSLab has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for QHSLab this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, QHSLab insiders have not sold or bought any company stock.

Percentage Held by Insiders

74.19% of the stock of QHSLab is held by insiders. A high percentage of insider ownership can be a sign of company health.

USAQ Stock Analysis - Frequently Asked Questions

How have USAQ shares performed this year?

QHSLab's stock was trading at $0.2480 at the beginning of 2025. Since then, USAQ stock has decreased by 15.3% and is now trading at $0.21.

How were QHSLab's earnings last quarter?

QHSLab, Inc. (OTCMKTS:USAQ) released its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm earned $0.65 million during the quarter.

How do I buy shares of QHSLab?

Shares of USAQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of QHSLab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that QHSLab investors own include Amer Prem Water (HIPH), Ultrack Systems (MJLB), Meta Platforms (META), Isracann Biosciences (ISCNF), International Land Alliance (ILAL), Leef Brands (ICNAF) and Gemini Group Global (GMNI).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:USAQ
• CIK: 856984
• Web: www.usaqcorp.com
• Phone: (929) 379-6503
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$260 thousand
• Net Margins: -14.03%
• Pretax Margin: -13.99%
• Return on Equity: N/A
• Return on Assets: -18.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: $2.13 million
• Price / Sales: 1.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -3.50

Miscellaneous

• Outstanding Shares: 10,590,000
• Free Float: 2,734,000
• Market Cap: $2.22 million
• Optionable: Not Optionable
• Beta: 0.70